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Abstract 
 The aim of this thesis is to examine the mechanisms of Methylphenidate (MPH) on 
Conditioned Place Preference (CPP), a behavioral test of reward. The psychostimulant MPH is 
therapeutically used in the treatment of ADHD, but has been implicated in many 
pharmacological actions related to drug addiction and is considered to have abuse potential. Past 
work in our lab and others have shown substantial sex-differences in the neuropharmacological 
profile of MPH. Here a discussion of the relevant mechanisms of action of MPH and its 
relationship to neurotrophins and CPP are reviewed. Furthermore, previous work is reviewed and 
a rationale for two experiments are presented. The study resulted in two experiments conducted 
earlier this year. Each experiment is presented, examining sex differences in CPP in two different 
methodological paradigms as well as the effects of MPH on levels of the dopamine transporter 
(DAT) in striatal and accumbal neurons. 
Introduction  
 Methylphenidate (MPH) is a psychostimulant sold under the trade-name Ritalin. This 
class of drugs also includes cocaine, amphetamine, and methamphetamine. MPH is clinically 
prescribed for the treatment of ADHD and narcolepsy. It is one of the most commonly prescribed 
medications for ADHD. An estimated 6% of school-aged children are prescribed with either 
MPH or amphetamine, with MPH representing nearly 90% of psychostimulant prescriptions 
(Volkow and Swanson 2003, Zito et al. 2000). In the 1990s, there was a five-fold increase in the 
number of children who were prescribed psychostimulants leading to concern about the long-
term effects of psychostimulant prescription among children (Mayes et al. 2008). 
 At present no biomedical lab test exists for diagnosis of ADHD. Diagnosis historically 
has been based on the observation of behavioral symptoms which are common in children 
Watson 3 
(Mayes et al. 2008, Tripp and Wickens 2009). Furthermore, there is a lack of homogeneity in 
many study populations leading some researchers to question the existence of a unified etiology 
(Tripp and Wickens 2009). MPH is clinically effective and safe for ADHD symptoms; however, 
rising rates of prescription are cause for concern. Furthermore, due to ambiguity of symptoms 
and diagnostic and treatment styles of physicians, ADHD has been severely over-diagnosed and 
under-diagnosed in different geographic regions (Mayes et al. 2008).  
Though there is still extensive debate, salient features of ADHD are widely agreed upon. 
Broad deficits in executive function and altered reward and motivation have been thought to 
underlie many symptoms of ADHD (Barkley 1997, Tripp and Wickens 2009) Clinical doses of 
MPH may serve to balance neurotransmitter release in the prefrontal cortex (PFC) thus relieving 
executive function deficits (Berridge and Devilbiss 2006). An altered response to reinforcement 
has also been demonstrated in children with ADHD and several models have been proposed in 
which altered sensitivity to reinforcement is a cardinal symptom (Luman et al. 2005). Stronger 
preference for immediate reinforcement over delayed reinforcement explain many of the 
symptoms of ADHD. Psychostimulants such as MPH have been shown to selectively control the 
efficacy of conditioned reinforcement (Hill 1970, Robbins 1975, Tripp and Wickens 2009). 
However, research has shown that MPH has a similar neuropharmacological profile to that of 
commonly abused drugs such as cocaine and amphetamine. This combined with rising rates of 
prescription has raised concerns of the abuse potential of MPH (Volkow et al. 1999) The rising 
rates of prescription of adolescents require greater study into the long term effects of MPH in 
adolescents. Earlier ages of prescription and longer treatment durations may affect 
developmental processes into adulthood, leading to structural changes and long-term behavioral 
changes (Scherer et al. 2010, Zito et al. 2000). Thus a primary goal of the research presented here 
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is to investigate possible mechanisms of action that may elucidate the effects of MPH on abuse 
potential and developmental outcome. 
Abuse of MPH has been a cause of concern in recent years due to its availability. In one 
study, about 20% of patients ages 12-18 in an addiction center were determined to have misused 
MPH for recreational purposes. About 5% were diagnosed as MPH abusers. Despite lower rates 
of abuse relative to other psychostimulants such as cocaine, MPH still shows significant abuse 
potential (Williams et al. 2004). In 2002 it was found that approximately 7.3 million persons in 
the United States aged 12 and older had misused ADHD medications. These abused drugs were 
usually psychostimulants prescribed for ADHD, with MPH being the most popular (Kroutil et al. 
2006) The speed of change in blood-serum levels which can be attained through intravenous or 
intranasal use may increase potential for addiction (Volkow and Swanson 2003). These routes of 
administration are more common for non-medical usage of stimulants and there is evidence that 
MPH may be more dangerous than cocaine and amphetamine when used in this way (Parran and 
Jasinski 1991). 
Rates of prescriptions for MPH in the United States and Canada have risen dramatically 
since the early 1990s (Poulin et al. 2001). However, the long-term effects of MPH have not been 
studied sufficiently. There is also some evidence that chronic usage of MPH during adolescence 
may have lasting behavioral consequences. Chronic MPH exposure during development has been 
linked to decreased sensitivity to rewarding stimuli and enhanced sensitivity to aversive 
situations (Bolaños et al. 2003). Thus with rising rates of prescription, it is important to further 
study the potential neurological changes resulting from accepted use and abuse of MPH. 
Methylphenidate Mechanism and Neurotrophic Effects 
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 The primary effects of MPH are due to inhibition of the dopamine transporter (DAT) as 
well as the norepinephrine transporter (NET). Binding to these transporters serves to block 
reuptake of post synaptic dopamine and norepinephrine leaving abnormally high extracellular 
levels of neurotransmitters in the synaptic cleft.  
 DAT is a critical transporter protein that removes extracellular DA released from the 
synapse, thereby lowering the levels of available DA. Furthermore, DAT levels may vary in 
different brain regions (Yang et al. 2007). Due to blockage of the DAT, extracellular DA levels 
are thought to accumulate in cellular medium. Heightened DA availability increases binding to 
cellular DA receptors. Furthermore, extracellular DA concentrations have been shown to be 
significantly higher in the human brain after a therapeutic dose of MPH was given. Researchers 
found that extracellular DA was increased in the striatum, a key brain area for reward activity 
(Volkow et al. 2001). Further elucidating the DAT role in the therapeutic efficacy of MPH is 
research showing that patients with ADHD have significantly elevated levels of striatal DAT 
(Krause et al. 2000, Dougherty et al., 1999). These findings may be particularly relevant to 
MPH’s therapeutic efficacy because DA levels in the striatum have been shown to affect the 
signal-to-noise ratio of striatal cells (Kiyatkin and Rebec 1996). Patients with ADHD may 
therefore have increased levels of extracellular DA occupying a higher percentage of DAT when 
taking methylphenidate and thus have reduced background cell firing rates and enhanced 
synchronous goal-seeking neuronal activity (Volkow et al. 2001). In a past study DA increase 
was significant in all subjects, but highly variable. In particular, it is important to note that all 
subjects were healthy controls although there is little reason to think that oral MPH would act 
differently on DAT in patients with ADHD (Volkow et al. 2001). However, this is relevant to our 
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experimental model that focuses more closely on the abuse potential of MPH than on therapeutic 
action for ADHD.  
 The pharmacokinetics of MPH and route of administration may be important to 
explaining its abuse potential. A therapeutic dose of oral MPH is generally 0.25-1 mg/kg. This 
dosage has been shown to potently block 50%-75% of DAT receptors in humans (Volkow et al. 
1998). Oral MPH reaches peak concentrations in the brain after 60 minutes, however intravenous 
MPH has been shown to reach peak concentrations within 8-10 minutes (Volkow et al. 1995). 
Perhaps most importantly the affinity with which MPH blocks DAT has been shown to have a 
similar psychopharmacological potency to that of cocaine (Volkow et al. 1998). Supporting this 
research, it has been shown that there is a significant relationship between self-reports of a 
rewarding “high” and DA increases with intravenous MPH administration in particular (Volkow 
et al. 1999). 
 Relatively little research has been done on sex differences in response to MPH treatment. 
Most research with MPH has been conducted with male rodents due to the greater interactive 
complexity of female's reproductive cycles (Askenasy et al. 2007, Dafny and Yang 2006). 
Wooters et al. have shown that adult female rats show significantly greater conditioned 
locomotor hyperactivity than adult males when given a 3 mg/kg dose of MPH (2006). Because of 
rising prescriptions in adolescents, and the abuse potential of MPH, findings describing enduring 
effects from adolescence are especially relevant. Using conditioned place preference (CPP), a 
behavioral test of reward, chronic exposure to a 2 mg/kg dose of MPH during adolescence 
showed aversions to cocaine-paired environments in males, but showed preference to cocaine-
paired environments in female rats Brenhouse et al. (2009). Furthermore, there are substantial 
sex differences in the development of DA receptor systems through adolescence. Male rats have 
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significantly greater overproduction of D1 and D2 receptors in the Striatum and NAc. The 
increase in male DA receptors during development parallels early motor symptoms of ADHD 
which may explain the much higher prevalence rate of ADHD in men than women. (Anderson 
and Teicher 2000). Thus another major element of the studies presented here is to delineate 
further effects of MPH on sex differences. 
Neurotrophins 
Psychostimulants such as MPH are known to affect a class of proteins known as 
neurotrophins (Golden and Russo 2012, Scherer et al. 2010, Messer et al. 2000). Neurotrophins 
have an important role as neuronal growth factors aiding in maintenance and cell survival as well 
as synaptic plasticity during development and learning and memory (Bolaños and Nestler 2004). 
In particular, the neurotrophins Brain-derived neurotrophic factor (BDNF) and Glial cell-line 
derived neurotrophic factor (GDNF) are important because these have been implicated in a wide 
variety of brain functions, psychiatric disorders and in the incubation of drug craving (Pickens et 
al. 2011).  
BDNF is expressed throughout the brain. BDNF has notable effects in midbrain 
dopamine neurons key to motivation and locomotor activity such as the ventral tegmental area in 
high levels and the NAc and Striatum at lower levels. Thus it has been hypothesized that BDNF 
is involved in synaptic plasticity changes related to drug addiction and substance abuse (Bolaños 
and Nestler 2004). Behavioral changes associated with addiction may be a consequence of long-
term restructuring of molecular and cellular processes in reward circuits induced by repeated 
exposure to drugs, essentially a phenomenon of neural plasticity. BDNF activity within the 
midbrain dopaminergic system plays a critical role in changing plasticity reflected in reward, 
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sensitization (a factor in the development of drug craving), and drug motivated behavior (Pickens 
et al. 2011, Horger et al. 1999, Guillin et al. 2001, Nestler 2001). 
BDNF functions by activating the tyrosine kinase (Trk) family receptor, TrkB. Activation 
of Trk receptors leads to several downstream cellular signaling cascades that regulate neuronal 
excitability, cytoskeletal organization, synaptic connections, and gene expression (Bonni and 
Greenberg 1997, Bolaños and Nestler 2004, Kaplan and Miller 2000, Pickens et al. 2011). The 
TrkB receptor is highly expressed throughout dopaminergic neurons in the midbrain, including 
regions such as the VTA, PFC, and to a lesser extent in the NAc and striatum. Thus, many 
neurotrophic functions due to BDNF take place in the VTA-NAc circuit (Hyman et al. 1994, 
Bolaños and Nestler 2004). This VTA-NAc pathway forms the core of the 'motive circuit' and is 
a major part of the mesolimbic DA system. The primary structures which make up the circuit are 
the Ventral Tegmental Area (VTA), Nucleus Accumbens (NAc), Ventral Palladium (VP), and 
Prefrontal Cortex (PFC). Each structure is critical in transforming biological stimuli into 
adaptive behavioral responses and their functioning is reviewed in greater detail elsewhere 
(Kalivas and Volkow 2005, Pierce and Kalivas 1997).  
 Drugs of abuse potently activate the mesolimbic dopamine system and cause long-term 
neuroadaptation throughout the motive circuit pathways after repeated use (Pickens et al. 2011). 
Recent evidence has shown that time-dependent BDNF protein levels in the VTA, NAc, and 
amygdala correlate with time-dependent increases in cocaine seeking during the first 90 days of 
drug withdrawal (Grimm et al. 2003). Cocaine and amphetamine have also been shown to have 
significant neural plastic effects on the cell bodies of VTA dopamine neurons. Cocaine increases 
the number of dendritic branches and spines on neurons in the NAc and the prefrontal cortex. 
This morphological alteration may persist in drug self-administration in animals for at least one 
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month after the last drug exposure thus showing evidence of the enduring neuroplastic effects of 
BDNF (Robinson and Kolb 1997, Robinson et al. 2001).  
Furthermore, an increase of BDNF and TrkB signaling is noted in the NAc following 
both self-administration, and intraperitoneal (ip) administration of cocaine. Conversely, BDNF 
infusion into the NAc led to increased cocaine self-administration. Thus, dynamic changes of 
BDNF levels in the NAc promotes addictive behavior, highlighting the profound effects of 
neuroplasticity within core motivational regions (Graham et al. 2007). Due to the 
pharmacological similarity of MPH to cocaine these findings are significant and may apply more 
generally to processes involved with psychostimulant addiction. 
The motive circuit's prominent role in processing reward and directing motor action 
constitute an interface between the limbic and motor systems (Mogenson et al. 1993). Thus, 
many psychostimulant drugs which activate the mesolimbic dopamine system induce behavioral 
sensitization. Behavioral sensitization refers to the phenomenon of enduring progressive 
increases in behavioral response to many drugs of abuse due to chronic exposure to the drug. 
Evidence shows that repeated exposure to MPH induces behavioral sensitization (Vanderschuren 
and Kalivas 2000, Yang et al. 2007, Dafny and Yang 2006).  
The brain circuitry involved in sensitization is not yet fully understood. However, 
psychostimulants with rewarding properties have been shown to activate midbrain dopaminergic 
systems. Blocking D1 and D2 receptors was shown to inhibit sensitization to MPH, indicating 
that sensitization occurred to rewarding properties of dopamine (Meririnne et al. 2001). 
Sensitization in other psychostimulants appears to be mediated by DA signaling as well 
(Vanderschuren and Kalivas 2000). Infusions of BDNF into the VTA dramatically enhance the 
locomotor sensitization and rewarding effects of acute and chronic cocaine exposure using a CPP 
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paradigm. In contrast VTA infusions of Nerve-Growth Factor (NGF), another neurotrophin, did 
not show alterations in morphine or cocaine’s actions in the VTA, suggesting that BDNF plays a 
primary role in sensitization (Horger et al. 1999). Behavioral sensitization may represent early 
changes in neuronal plasticity in motivation and reward neural circuits underlying long term 
changes associated with drug addiction. Thus there is substantial overlap between the processes 
of reward, sensitization, and addiction within mesolimbic circuits, though distinct mechanisms 
can be identified with various methodologies (Dafny and Yang 2006, Kalivas and Volkow 2005).  
Conditioned Place Preference Testing 
 By using classical conditioning principles, CPP provides a valuable methodology to study 
drug reward. In CPP the rewarding properties of a drug or non-drug mechanism act as an 
unconditioned stimulus (US). This treatment is contiguously paired with neutral environmental 
cues that acquire an association with the natural rewarding properties of the US and act as 
conditioned stimuli (CS). Subsequent exposure to previously neutral environmental contexts 
elicits approach behavior if preference was established. Alternatively, motivated withdrawal may 
occur if conditioned place aversion (CPA) was established (Tzschentke 1998). These response 
tendencies are evolutionarily pre-programmed as specific reactions to aversive or rewarding 
stimuli. Increased time spent in the US-paired context indicates preference and thus a rewarding 
effect, the converse indicates aversion (Bardo and Bevins 2000). 
 A standard CPP experiment pairs alternative treatments in at least two distinct contexts. A 
rewarding treatment (drug, food, or other appetitive stimulus) is given while animals are placed 
into one context. Generally a saline control treatment is given to another animal group in the 
other context. This pairing can be done a single time or more frequently to mimic chronic 
stimulus exposure. After an initial conditioning, a post-test round is performed, this time with 
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animals allowed to freely traverse the three arenas. An increase in time spent in the stimulus-
paired context indicates preference and thus, reward (Bardo and Bevins 2000, Tzschentke 1998). 
Behavior changes emerge from temporal pairing of environmental context and the 
stimulus reward. The context environment is a complex multi-modal CS of various sensory cues. 
Context environments are usually arenas built with variable flooring or coloring on the walls. 
Texture may also be a feature of the environmental context. Beyond physical cues, researchers 
must also consider the extent to which novelty as a motivational factor might affect different 
drug tests (Tzschentke 1998). Because rats prefer novel over familiar environments, this can 
serve as a confounding factor in CPP testing. Since rats may not have developed familiarization 
to the context in which drug-pairing occurred, during the drug-free testing day animals may 
show preference to the drug-paired context due to novelty rather than reward (Bardo and Bevins 
2000, Parker 1992). Designing an apparatus with three discrete contexts, a novel, a drug-paired, 
and a saline-paired compartment can mitigate this bias. During the test day, animals typically 
show preference to the rewarding drug over the novel environment (Bardo and Bevins 2000). An 
unbiased procedure was used in the current study. 
Because of the contiguous relationship with a conditioned context, CPP is ideal for 
investigating the temporal profile of reward. Cocaine, for instance, produces CPP if given 
immediately or five minutes prior to placement in a context, but produces CPA if administered 
15 minutes prior, thus revealing thus supporting an opponent-process model of reward in cocaine 
consistent with self-reports of “high” and generally more negative after effects. Thus CPP's 
sensitivity to reward allows for delineation of complex CS-US profiles which map to drug 
pharmacodynamics (Ettenberg et al. 1999). 
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Critically, CPP measures drug reward, but not reinforcement. Reward refers to the 
appetitive nature of a stimulus while reinforcement is a contingency that can increase the 
probability of a behavior (Bardo and Bevins 2000). Furthermore reinforcement paradigms such 
as self-administration requires multiple drug administrations before reliable behavioral 
measurements can be obtained which may affect receptor function relating to tolerance or 
sensitization. A major advantage of CPP is that it appears to be unique in its ability to measure 
drug reward after single conditioned pairing. Single context US pairing allows for determining 
drug reward without any induction of tolerance or sensitization. Furthermore physical 
dependence not required to obtain CPP. (Bardo and Bevins 2000). As a final note on the non-
isomorphism of CPP and self-administration, both have been shown to detect reinforcement in a 
unique set of substances, although there is large overlap (Bardo et al. 1999, Deroche et al. 1999).  
Rationale 
 The goal of these experiments were threefold. The first was to analyze sex differences in 
CPP with high doses of MPH (5 mg/kg). This dosage is decidedly higher than an established 
clinical dose so as to represent an abused dosage (Brown et al. 2012). When MPH is abused it is 
often taken at doses significantly higher than clinical usage. Approximately 75% of MPH abusers 
take the drug through intranasal administration, thus avoiding first pass metabolism and 
increasing bioavailability of MPH (Bright 2008, Brown et al. 2012). Previous research has found 
that MPH reliably produces CPP (Meririnne et al., 2001, Wooters et al. 2011). As a 
psychostimulant, this is unsurprising. Many other psychostimulant DA-reuptake blocking drugs 
have been used for CPP as well (Tzschentke 1998). The use of CPP may show sex-differences in 
the rewarding effects of MPH that align with previous findings on sex-differences in 
sensitization. In previous work from our lab it was shown that in a clinical dose (1 mg/kg) 
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resulted in locomotor suppression in both sexes. For higher doses, however (3 mg/kg and 5 
mg/kg), female rats showed significantly greater locomotor sensitization (Brown et al. 2012). 
Others have also found sex differences in MPH sensitization (Chelaru et al. 2012, Wooters et al. 
2006). Thus, based off past work it was hypothesized that female rats given a high dose would 
show more robust CPP than male rats given the same dose (Brown et al. 2012). 
A second purpose was to analyze different methodological paradigms of CPP in response 
to MPH. In the every second day conditioning study, the non-conditioning day may simulate the 
generally larger time intervals between recreational MPH use (Brown et al. 2012). Additionally, 
previous work in our lab studying sensitization used an every second day conditioning paradigm 
for CPP testing. As mentioned above, this paradigm has shown more robust sensitization to a 5 
mg/kg dose of MPH in adolescent female rats as compared to male rats. Locomotor tracking 
showed that sensitization to MPH peaked on the fifth day of treatment (Brown et al. 2012).  
This is interesting because past research has shown that heightened sensitization typically 
indicates more robust dopamine responses in brain areas associated with drug reward 
(Vanderschuren and Kalivas 2000, Kalivas and Duffy 1993). Brain plasticity changes reflecting 
reward and the incubation of drug craving may arise during drug withdrawal. Previous work has 
shown increased sensitization in response to MPH, related to underlying mechanisms involving 
BDNF and reward (Brown et al. 2012) Thus, it was hypothesized that brain plasticity changes in 
reward circuits would occur during the non-testing days, thus showing more robust CPP in 
females as compared to males which reflect changes observed in sensitization (Cummins et al. 
2013). 
A final purpose was to examine the effects of MPH on DAT levels in male and female 
adolescent rats. Blockage of the DAT is the primary mechanism of action of MPH, however 
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research has shown a decrease in the actual density of the DAT following MPH treatment in both 
adults and adolescents (Izenwasser et al. 1999, Moll et al. 2001). Research has shown a dose-
dependent decrease in striatal DAT to MPH. However, DAT levels in the NAc were not tested 
(Nikolaus et al. 2007). The NAc is of primary importance for drug reward and plays a central 
role in the function of the motive circuit (Pierce and Kalivas 1997). Lower levels of the DAT will 
have a direct impact on dopaminergic activity in the synapse. Doses more relevant to abused 
MPH may show greater changes in DAT levels. Furthermore, there is no data on sex differences 
in DAT density due to MPH exposure. Past research has shown sex differences in conditioning 
due to MPH as well as sex differences in behavioral response and dopaminergic function to 
psychostimulants (Wooters et al. 2006, Becker 1999). Thus we hypothesized that females would 
show a decrease in the DAT levels in the Dorsal Striatum and the NAc compared to male rats.  
Methods 
Two experiments were conducted to determine the effects of MPH on CPP. In the first 
experiment, saline control animals and animals given a clinically relevant 1 mg/kg dose were 
compared to 5 mg/kg, a dose more relevant to abuse. DAT was measured from animals in the 
first experiment. In the second experiment, all animals were either given a 5 mg/kg dose or saline 
as a control. The CPP paradigm in the second experiment was switched to an every-other 
conditioning day paradigm. 
 In each group 8 Sprague-Dawley rats were used. The gender of the rodents was split 
evenly in all groups. Rats were tested during adolescence, defined as development between 
postnatal days (P)28 to P60 for rats (Smith 2003). Conditioning in the first experiment took place 
every day from P44-48. The second experiment was conducted every second day during days 
P33-41. This was done so that a more complete range of adolescent development could be tested. 
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 For CPP testing in these studies a three-chambered apparatus was used with identical 
dimensions in three visually distinct environmental contexts. Locomotor arenas were rectangular 
wooden boxes with square compartments measuring 30 cm on a side. An additional compartment 
was used to provide novelty in addition to the drug-paired compartment and saline-paired 
compartment to eliminate the confounding effect of novelty-seeking in rats (Bardo and Bevins 
2000). Removable dividers separated each context. Tactile surface was also distinct in each 
context. 
 For the first experiment animals were given an initial preference test on P43.This was to 
determine if there was an initial context which was preferred by the animal. An ip Saline 
injection was given and the animals were placed into the apparatus without context dividers and 
allowed to freely explore for a 10 minute period. No initial context preference was demonstrated 
by any group (Cummins et al. 2013). 
 Beginning the day after initial preference testing, dividers were replaced into the 
apparatus and conditioning tests were conducted. Each animal was assigned randomly to the 
horizontal or vertical environmental context. For animals given MPH, the context temporally 
paired with MPH was the paired context, the saline-paired context was the unpaired context. 
Control animals were given saline in both contexts. On each conditioning day a morning session 
was done where all animals were given saline and placed into their initial assigned context for a 
10 min trial. In the afternoon session animals in the MPH group were administered either 1 
mg/kg or 5 mg/kg MPH and 10 min later placed into their assigned context for a 10 min trial. 
Assignment of paired contexts were balanced across animals to prevent bias (Cummins et al. 
2013). 
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 After conditioning trials were complete, a post-conditioning preference test was 
conducted on P49. This test was identical to the initial preference test, with dividers removed. All 
animals were administered ip of saline to control for stress of injection. Animals were then able 
to freely explore the apparatus. Animal behaviors were recorded as horizontal activity. The 
computer program Anymaze (from Stoelting Co, Woodale, IL) superimposed a grid on a digital 
video feed of the animals. Each time rats crossed a line it was counted as a locomotor activity 
count. During the post-conditioning preference test, the time spent in the paired context was 
divided by the time spent in both the paired and unpaired context as measured by Anymaze. This 
determined the preference ratio of the animals (Cummins et al. 2013).  
  To measure the effects of chronic MPH on the DAT in adolescence, one day after the 
post-conditioning test was conducted the animals in the consecutive-day paradigm were 
sacrificed. The dorsal striatum and NAc were dissected out of the brain and brain and tissue was 
analyzed. Analysis of DAT was conducted using a Western Blot assay. Measurement of the DAT 
was only performed on animals given 5 mg/kg because these showed CPP (Cummins et al. 
2013). 
 The second experiment was conducted with slight methodological differences. Again, 8 
Sprague-Dawley rats were used in each experimental group in even gender proportions. 
Conditioning days in this experiment were conditioned using an every second day paradigm. 
Conditioning for this experiment was identical to the first experiment, with a few exceptions. A 
clinical dose of 1 mg/kg was not used. Instead only saline control animals and 5 mg/kg MPH 
animals to directly compare the every second day paradigm with the every day paradigm in the 
context of an abused dose. Our lab had not shown sensitization to a clinical dose previously, so 
this dosage was not tested in the second experiment. The testing days occurred from P33-43, 
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with conditioning on every second day in order to test a wider developmental period. Each 
conditioning day had two sessions conducted identically to the first experiment (Cummins et al. 
2013). 
Results 
 In the first experiment, the preference ratios of rats given 1 mg/kg were not statistically 
different than those of rats given saline (Fig. 1). However, rats given the high 5 mg/kg dose 
showed significantly higher preference ratios, thus showing dose-dependent CPP to the drug-
paired contexts. Both male and female rats showed significantly greater CPP at this dose, but 
there was not a statistically significant sex difference between the two groups. Thus the 
hypothesis that CPP would mirror sex differences in sensitization based on previous findings was 
not shown to be true (Cummins et al. 2013). A two-way ANOVA (sex, drug) of the preference 
ratio revealed a significant main effect of adolescent drug treatment F(2,47)= 6.15, p <.005, but 
there was no significant main effect of sex nor an interaction of sex on adolescent drug treatment 
(Cummins et al. 2013). 
 For DAT density testing, a 5 mg/kg dose of MPH administered for five consecutive days 
showed significant effects on both the striatum NAc (Fig. 2). The Western Blot assay showed a 
significant decrease in the DAT in both the NAc and dorsal striatum. In females, DAT in the 
dorsal striatum was shown to decrease by 46.4%, while males showed a 44.3% decrease. In the 
NAc there was a 31.5% decrease in DAT for females and a 48.2% decrease for males. No prior 
studies have reported on the effects of MPH on DAT density in adolescence. There were no 
significant effects on DAT levels between genders (Cummins et al. 2013). A two-way ANOVA 
for the dorsal striatum resulted in a significant main effect of adolescent drug treatment F(1,34) = 
6.53, p < .016, but there were no significant main effects of sex or a significant interaction of sex 
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on adolescent drug treatment. For the NAc, a two-way ANOVA revealed a significant main effect 
of adolescent drug treatment F(1,34) = 6.16, p < .019, but again, no significant main effects of 
sex or an interaction of sex on adolescent drug treatment were found. 
 Interestingly the methodological change from a consecutive day conditioning paradigm 
of the first experiment to an every second day conditioning paradigm in the second experiment 
did not reveal significant sex differences in place preference (Fig. 3). A significant preference 
ratio was still shown in response to a 5 mg/kg dose. This difference was notable in that it was 
slightly lower, though not significantly so from the consecutive day 5 mg/kg group (Cummins et 
al. 2013). A two-way ANOVA revealed a significant main effect of adolescent drug treatment 
F(1,31)=10.59, p<.003. There was no significant main effects of sex nor a significant effect of 
sex on adolescent drug treatment. While MPH produced a significant increase in preference ratio 
in both male and females, no significant sex differences were found (Cummins et al. 2013).  
Discussion 
These experiments reveal several important findings related to the rewarding properties 
of MPH. As noted before, when taken recreationally, MPH may not be used consecutively. 
Additionally the greater dosage and ip route of administration is more relevant to an abused dose 
(Brown et al. 2012). Our results show that a similar magnitude of place preference can be 
established with non-consecutive MPH exposure in rats. The dopamine deficit mentioned before 
is a generally accepted model of ADHD (Tripp and Wickens 2009). However, an animal model 
of ADHD was not used here. Thus these findings may be of more relevance to recreational use of 
MPH.  
The results of the consecutive day CPP experiment showed that place preference to a 5 
mg/kg dose of MPH is not significantly modulated by gender. This is in contrast to our 
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hypothesis because previous findings in our lab and others, have revealed sex differences to 
MPH sensitization at 5 mg/kg (Brown et al. 2012). Chelaru et al. (2012) also found sensitization 
to be enhanced in female rats as compared to male rats at a 2.5 mg/kg dose. Thus it is clear that 
there are sex differences in behavior in response to MPH. These findings highlight the 
differences between CPP and sensitization, despite the reliance of both on mesolimbic 
dopaminergic activity. Sensitization represents the arousing effects of drugs of reward, while 
CPP denotes reward in relation to a particular context. Further research will reveal the complex 
interaction of reward and gender. 
Western blot analysis of DAT levels showed reduction of DAT densities in the dorsal 
striatum and NAC. This may result in increased availability of synaptic dopamine in these areas. 
This would lead to an enhanced rewarding effect. Thus recreational use of MPH in adolescents 
may experience greater reward and thus be in greater danger for addiction than in clinically 
relevant usage of MPH. A review of the incubation of drug craving can be found in Pickens et al. 
(2011). Reduction of the DAT in reward areas has the additional consequence of affecting the 
long-term development of the brain's reward system. Other studies have shown that prenatal 
exposure to MPH results in an increased response to rewarding stimuli into adulthood (Crawford 
et al. 2007). The long-term effect of reduced DAT during adolescence has yet to be fully studied, 
but may play a role in in this effect. 
The results of the every second day CPP paradigm indicate that conditioned place 
preference in response to a 5 mg/kg was not significantly affected by a modified dosing regimen. 
The small age difference between the two rat groups may appear irrelevant, but the adolescent 
model represents a broad period of rapid dopaminergic development (Andersen & Teicher, 
2000). Slightly different behavioral changes were noted between the two CPP paradigms, 
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however the magnitude of reward was not significantly affected across the wider developmental 
period tested (P33-49 for both groups combined) or the spaced dosing regimen. 
 In conclusion, the research presented here reviews experiments conducted in our lab on 
the effects of MPH on CPP. A high dose, representing an abused dose of MPH recreationally, 
produced CPP in both male and female adolescent rats. There were no sex differences in the 
preference ratio for animals treated with MPH. Furthermore, CPP occurred at the same 
magnitude regardless of MPH administration by a consecutive day or every second day exposure 
paradigm. This high dose of MPH also produced significant decreases in the DAT in both the 
dorsal striatum and NAc, key reward centers of the brain. Thus an increase in overall 
dopaminergic activity can occur, increasing the potential for addiction to MPH. Changes in the 
DAT system in adolescents may also lead to altered response to behavior later in life. Despite the 
lack of significant sex-differences to CPP in this study, there are clear sex differences in behavior 
to MPH. Further research will help clarify the complex relationship between gender, age, and 
addiction. 
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Fig. 1. Preference ratio is presented as a function of group for the post-conditioning preference 
test in the consecutive day paradigm. Asterisk (*) indicates that the group mean was significantly 
higher than the 1 mg/kg MPH group and the saline control group. 
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Fig. 2. The DAT is presented as a ratio to total protein for both brain dorsal striatum and NAc. 
Asterisk (*) indicates that control group mean was significantly higher than drug treatment 
group. 
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 Fig. 3. Preference ratio is presented as a function of group for the post-conditioning 
preference test in the every second day paradigm. Asterisk (*) indicates group mean was 
significantly greater than saline control group. 
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